Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It … Read more
Lincoln Pharmaceuticals Limited (LINCOLN) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.39 Billion INR
Based on the latest financial reports, Lincoln Pharmaceuticals Limited (LINCOLN) has total liabilities worth ₹1.39 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lincoln Pharmaceuticals Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Lincoln Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lincoln Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Lincoln Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Hain Celestial Group Inc
NASDAQ:HAIN
|
USA | $1.15 Billion |
|
NNIT A/S
LSE:0R5Z
|
UK | Dkr1.65 Billion |
|
High Tech Pharm Co. Ltd
KQ:106190
|
Korea | ₩12.57 Billion |
|
Cox Energy América, S.A.B. de C.V.
MC:COXE
|
Spain | €10.33 Billion |
|
Wieson Technologies Co Ltd
TWO:6272
|
Taiwan | NT$2.52 Billion |
|
UBcare. Co. Ltd
KQ:032620
|
Korea | ₩72.26 Billion |
|
Cabral Gold Inc
PINK:CBGZF
|
USA | $1.78 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Lincoln Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lincoln Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lincoln Pharmaceuticals Limited (2006–2025)
The table below shows the annual total liabilities of Lincoln Pharmaceuticals Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹1.25 Billion | +16.64% |
| 2024-03-31 | ₹1.07 Billion | +26.50% |
| 2023-03-31 | ₹849.46 Million | -16.29% |
| 2022-03-31 | ₹1.01 Billion | +18.05% |
| 2021-03-31 | ₹859.67 Million | +13.24% |
| 2020-03-31 | ₹759.17 Million | -20.54% |
| 2019-03-31 | ₹955.43 Million | -22.13% |
| 2018-03-31 | ₹1.23 Billion | +8.91% |
| 2017-03-31 | ₹1.13 Billion | -15.97% |
| 2016-03-31 | ₹1.34 Billion | -6.76% |
| 2015-03-31 | ₹1.44 Billion | -8.55% |
| 2014-03-31 | ₹1.57 Billion | +9.65% |
| 2013-03-31 | ₹1.43 Billion | +10.24% |
| 2012-03-31 | ₹1.30 Billion | +47.04% |
| 2011-03-31 | ₹884.65 Million | +53.47% |
| 2010-03-31 | ₹576.43 Million | +57.54% |
| 2009-03-31 | ₹365.89 Million | +26.62% |
| 2008-03-31 | ₹288.97 Million | +8.75% |
| 2007-03-31 | ₹265.73 Million | +4.56% |
| 2006-03-31 | ₹254.13 Million | -- |